BioSpeedia is a biotechnology company founded by two scientific researchers from Institut Pasteur.
We develop and manufacture a portfolio of innovative in vitro diagnostics rapid test kits for medical professionals and clinical diagnostic markets worldwide.
Established in 2011, BioSpeedia develops and manufactures a portfolio of innovative in vitro diagnostics (IVD) rapid test kits and ELISA kits for medical professionals and clinical diagnostic markets worldwide.
CE marked COVID-19 rapid test kits
Our Rapid Antibody Test Kit is an immunochromatographic assay designed for the qualitative detection and differentiation of specific IgM and IgG antibodies to coronavirus 2019-nCoV or SARS-CoV-2 in human fingertip blood samples. It is intended to be used for the detection of SARS-CoV-2 virus infection. This protocol can be carried out in 15 minutes and is simple in its implementation.
Our Rapid Antigen Test Kit is an immunochromatographic assay designed for the qualitative detection of specific SARS-CoV-2 antigen in human nasopharyngeal swab specimen. It is intended to be used for the detection of SARS-CoV-2 virus infection. This protocol can be carried out in 15 minutes and is simple in its implementation.
Our PCR Test Kit offers a combination of GF-1 Viral Nucleic Acid Extraction Kit and 2019 nCoV Multiplex RT qPCR Kit, with the ability to complete the entire process from nucleic acid purification to RT-qPCR assay within 3.5 hours.
Biospeedia is partnering with SICPA® in developing a secured and certified health pass featuring COVID tests results to allow secured traveling.
SICPA® is a trusted global provider of security inks as well as a leader in secured identification, traceability and authentication solutions.
Biospeedia Test status data is revocable and thus always up to date. It
respects personal privacy concerns while providing incontrovertible
assurances of health status to the aviation and border authorities. The credential is authenticated by scanning a tamper proof QR code with a smartphone or a computer. The verification is independent of the document issuer. No personal or sensitive information is stored, either directly or encrypted, in any data base or on the blockchain and no extra infrastructure is required.
SICPA provides more than 85% of the world’s currency inks
World Health Organization (WHO) approved CSF test for meningitis
MeningoSpeed provides an immediate, easy to use and accurate rapid method for the diagnosis of N. meningitidis. The test can be completed in a few minutes as opposed to the current gold standard which can take 48 – 72 hours turnaround time, and up to a week more for serotyping.
Positive test for: